Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT
Allogeneic HSCT in patients with MDS or AML 70 years or older has a 3-year overall survival rate of 34%. Good performance status and CMV negativity of the patient result in improved outcome. The number of transplantations in this age group increases rapidly.